NCT Number: NCT03568656
Phase: Phase 1|Phase 2
Trial Summary: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast can – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): CellCentric Ltd.
Acronym:
Study to Evaluate CCS1477 in Advanced Tumours
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives